TX-ABS
20.7.2020 17:02:10 CEST | Business Wire | Press release
ABS today launches a unique suite of fleet management and vessel compliance services powered by smart functionality and advanced analytics which, in an industry first, will also be available through the new ABS App .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200720005501/en/
Designed to anticipate client needs and provide intuitive, informed decision support, the smart functionality is an enhancement to the ABS MyFreedom™ client portal and can be accessed through a mobile app or text. The portal and the industry’s most user-friendly digital tools simplify access to operational, technical and compliance fleet intelligence and all ABS Class services to manage the operating health and performance of fleets.
New industry-leading smart functionality launched today includes:
- The ABS Smart Scheduler™ , which leverages real-time AIS data to maintain fleet compliance and is the industry’s only mobile survey booking tool enabling any survey, including remote surveys, to be scheduled in less than a minute anytime, anywhere – even when there is no internet access. It tracks survey status for all vessels in a fleet and then issues alerts when surveys are due.
- Custom Checklist , which brings together port state data from all ABS-classed vessels to provide a port-specific checklist for crew and fleet managers prior to arrival at any port.
- Fee Estimator , which provides a comparison of estimated survey fees across multiple ports.
- Port State Control Risk , which provides customized port state control analytics by vessel or fleet. It allows clients to view their destination’s top deficiency items and the client vessel’s matching findings from ABS class records, along with a vessel risk rating based on compliance health status.
- International Safety Management (ISM) Findings , customized to individual vessel performance, which allows clients to view the destination port’s top ISM related deficiency items against their vessel’s matching findings from ABS class records.
- Port-Specific External Specialists , which provides one-touch direct client connections for upcoming surveys.
“Leveraging unprecedented access to data, we are delivering truly smart functionality that learns from the user and, with experience over time, anticipates future requirements, making it even easier to work with ABS,” said Christopher J. Wiernicki, ABS Chairman, President and CEO. “These are just the first of many enhancements and increased smart functionality that ABS will continue to deliver through the MyFreedom client portal. The portal brings together all of our clients’ Class needs digitally for a complete overview, so now it all clicks. Centralized and connected, it streamlines interactions with ABS, making our client experience straightforward and insightful.”
Offering enhanced risk management, compliance and operational efficiency through better informed decision making, MyFreedom delivers total fleet oversight, real-time survey status, smart scheduling, remote survey options, including annual surveys with mobile capture and collaboration, simplified access to compliance data and timely fleet certification renewals.
Visit our website for more information.
The ABS App is now available from the Apple App Store and Google Play .
▬▬
About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom